Top Investors Cut Paratek Pharmaceuticals, Inc. (PRTK) Holdings In June Quarter To Take Profit

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) went up to recover about 16.8% since recording its record low price of $9.38. The stock experienced 11.73% jump, arriving at $10.95 on 08/06/2018. During the day, the stock price traveled from $9.9 to $11. This company shares are 231.78% off its target price of $36.33 and the current market capitalization stands at $345.91M. The recent change has given its price a 4.73% lead over SMA 50 and -62.24% deficit over its 52-week high. The stock witnessed 3.79% gains, -1.79% declines and -20.94% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PRTK’s volatility during a week at 5.94% and during a month it has been found around 4.1%.

Paratek Pharmaceuticals, Inc. (PRTK) Top Holders

Institutional investors currently hold around $246 million or 85% in PRTK stock. Look at its top three institutional owners. Omega Fund Management, Llc owns $25.48 million in Paratek Pharmaceuticals, Inc., which represents roughly 7.37% of the company’s market cap and approximately 10.36% of the institutional ownership. Similar statistics are true for the second largest owner, Baupost Group Llc/Ma, which owns 2,394,498 shares of the stock are valued at $23.47 million. The third largest holder is Blackrock Inc., which currently holds $19.88 million worth of this stock and that ownership represents nearly 5.75% of its market capitalization.

Paratek Pharmaceuticals, Inc. 13F Filings

At the end of June reporting period, 78 institutional holders increased their position in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by some 5,160,048 shares, 46 decreased positions by 3,564,623 and 18 held positions by 16,405,796. That puts total institutional holdings at 25,130,467 shares, according to SEC filings. The stock grabbed 25 new institutional investments totaling 1,967,469 shares while 22 institutional investors sold out their entire positions totaling 2,232,794 shares.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Insider Trades

Multiple company employees have indulged in significant insider trading. Paratek Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chairman and CEO Bigham Michael has sold 22,500 shares of Paratek Pharmaceuticals, Inc. (PRTK) in trading session dated Jul. 02, 2018. These shares are worth $224,325 and were traded at $9.97 each. The SEC filing shows that Haskel William M. performed a sale of 7,323 shares. The Sr. VP, Sec. & General Counsel disposed these shares by way of transaction on Jul. 02, 2018. The company’s shares were given away at $9.97 per share worth to an income of some $73,010 on account of Haskel William M..

President, COO and CMO, Loh Evan, sold 12,000 common shares of Paratek Pharmaceuticals, Inc. (PRTK) in the open market. In a transaction dated Jul. 02, 2018, the shares were put up for sale at an average price of $9.97, raking in a sum of $119,640. After this sale, 202,786 common shares of PRTK are directly owned by the insider, with total stake valued at $2,220,507.

In the transaction dated Apr. 09, 2018, the great number of shares disposed came courtesy the Chairman and CEO; Bigham Michael disposed a total of 8,700 shares at an average price of $12.7, amounting to approximately $110,490. The insider now directly owns 199,730 shares worth $2,187,044.

Paratek Pharmaceuticals, Inc. (PRTK) Analyst Guide

Several analysts have released their opinion on Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), with 8 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.11 average brokerage recommendation.